Based on these inspiring results, NCCN recommended osimertinib for NSCLC patients with brain metastasis carrying EGFR sensitive mutations in the 3rd edition of guideline for Central Nervous System Cancers [29]. Here, EGFR is linked to non-small cell lung carcinoma.